Media stories about McKesson (NYSE:MCK) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. McKesson earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.5877083721359 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- The 50 Best Podcasts of 2017 (theatlantic.com)
- US law enforcement cracks down on opioid users, lets drug companies off the hook (wsws.org)
- BenchmarkPortal Certifies McKesson Specialty Health’s Third Party Logistics Service Center as Center of Excellence (markets.financialcontent.com)
- Wall Street Analyst’s Guidance: McKesson Corporation (MCK), Pioneer Natural Resources Co. (PXD) – Newburgh Gazette (newburghgazette.com)
- Ackerman & Co. Bolsters Retail Division with … – Digital Journal – Digital Journal (digitaljournal.com)
Several analysts recently weighed in on MCK shares. TheStreet lowered McKesson from a “b” rating to a “c+” rating in a report on Friday, August 25th. Jefferies Group set a $165.00 price target on McKesson and gave the company a “hold” rating in a report on Tuesday, August 29th. Needham & Company LLC upgraded McKesson from a “hold” rating to a “buy” rating and set a $179.00 price target on the stock in a report on Friday, September 8th. Morgan Stanley lowered McKesson from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $184.00 to $172.00 in a report on Thursday, September 14th. Finally, Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and increased their price target for the company from $175.00 to $178.00 in a report on Tuesday, September 19th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $174.31.
McKesson (NYSE:MCK) last released its earnings results on Thursday, October 26th. The company reported $3.28 earnings per share for the quarter, topping analysts’ consensus estimates of $2.78 by $0.50. McKesson had a return on equity of 24.87% and a net margin of 2.24%. The business had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.69 billion. During the same quarter last year, the firm posted $2.94 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. equities research analysts forecast that McKesson will post 12.19 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 2nd. Stockholders of record on Friday, December 1st will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Thursday, November 30th. McKesson’s payout ratio is 6.45%.
In other news, Chairman John H. Hammergren sold 65,000 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $160.00, for a total transaction of $10,400,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO John H. Hammergren sold 100,000 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $154.15, for a total value of $15,415,000.00. Following the transaction, the chief executive officer now directly owns 165,000 shares in the company, valued at approximately $25,434,750. The disclosure for this sale can be found here. Insiders have sold a total of 889,000 shares of company stock worth $136,890,860 in the last three months. Corporate insiders own 1.20% of the company’s stock.
McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.
What are top analysts saying about McKesson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for McKesson and related companies.